Relay Therapeutics (RLAY) Long-Term Investments (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Long-Term Investments data on file, last reported at $437.5 million in Q1 2026.

• On a quarterly basis, Long-Term Investments fell 29.07% year-over-year to $437.5 million in Q1 2026; TTM through Mar 2026 was $437.5 million, a 29.07% decrease from a year earlier, with the FY2025 full-year figure at $470.5 million, down 28.39% from the prior year.
• Long-Term Investments for Q1 2026 stood at $437.5 million, down from $470.5 million in the prior quarter.
• Over the last five years, Long-Term Investments for RLAY reached as high as $847.1 million in Q4 2022 and fell as low as $437.5 million in Q1 2026.
• Historically, Long-Term Investments has averaged $640.6 million across 5 years, with a median of $657.0 million in 2024.
• Across the five-year window, Long-Term Investments jumped 80.22% in 2022 and retreated 29.07% in 2026, its largest moves.
• Year by year, Long-Term Investments stood at $847.1 million in 2022, then retreated by 28.42% to $606.4 million in 2023, then gained by 8.36% to $657.0 million in 2024, then declined by 28.39% to $470.5 million in 2025, then fell by 7.02% to $437.5 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $437.5 million in Q1 2026, $470.5 million in Q4 2025, and $504.9 million in Q3 2025.